NVG, LLC

Lobbying for NOVO NORDISK INC. · Pharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $80,000.00 income · posted Apr 20, 2026

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare coverage of Anti-Obesity Medicines.

Health Issues

Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.